Mineralys Therapeutics In... (MLYS)
9.54
0.42 (4.61%)
At close: Jan 15, 2025, 10:00 AM
Company Description
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases.
It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension.
The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Mineralys Therapeutics Inc.
| Country | United States |
| IPO Date | Feb 10, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Jon Congleton |
Contact Details
Address: 150 N. Radnor Chester Rd. Radnor, Pennsylvania United States | |
| Website | https://mineralystx.com |
Stock Details
| Ticker Symbol | MLYS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001933414 |
| CUSIP Number | 603170101 |
| ISIN Number | US6031701013 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jon Congleton | Chief Executive Officer & Director |
| Adam Scott Levy | Chief Financial Officer & Secretary |
| Cindy Berejikian | Executive Vice President of Operations |
| Danielle Bradbury | Senior Vice President of Quality Assurance |
| Dr. Brian Taylor Slingsby M.D., M.P.H., Ph.D. | Founder & Executive Chairman |
| Dr. David M. Rodman M.D. | Chief Medical Officer |
| Dr. Robert McKean Ph.D. | Senior Vice President of CMC |
| Jeffrey N. Fellows | Senior Vice President of Regulatory Affairs |
| Jessica Ibbitson | Senior Vice President of Clinical Operations |
| Sarah Foster | Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 08, 2025 | 8-K | Current Report |
| Jan 07, 2025 | 4 | Filing |
| Dec 13, 2024 | 4 | Filing |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 4 | Filing |
| Nov 12, 2024 | S-8 | Filing |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |